Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma
Qi Li, Wei Wang, Yusuke Machino, Tadaaki Yamada, Kenji Kita, Masanobu Oshima, Yoshitaka Sekido, Mami Tsuchiya, Yui Suzuki, Ken-ichiro Nan-ya, Shigeru Iida, Kazuyasu Nakamura, Shotaro Iwakiri, Kazumi Itoi and Seiji Yano
Article first published online: 18 DEC 2014 | DOI: 10.1111/cas.12575
In this study, the anti-GM2 antibody BIW-8962 first showed a significant ADCC activity against malignant pleural mesothelioma (MPM) cell line and therapeutic activity in an in vivo orthotropic mouse model using the cell line. Additionally, the GM2 expression was confirmed in the MPM clinical specimens. These data suggest that anti-GM2 antibodies may become a therapeutic option for MPM patients.